63.5 F
Pakistan
Wednesday, November 18, 2026
HomeBusinessOnward Therapeutics Closes NT$900 Million (approximately US$28 Million) Series B Financing to...

Onward Therapeutics Closes NT$900 Million (approximately US$28 Million) Series B Financing to Advance Clinical-Stage Oncology Pipeline

First capital increase since relocating global headquarters to Taiwan; Company targets Emerging Stock Board registration by the end of 2027 TAIPEI and EPALINGES, Switzerland and PARIS, Nov. 18, 2026 /PRNewswire/ — Onward Therapeutics, Inc. (“Onward Therapeutics” or the “Company”) today. ..

Read full story on Pr Newswire Apac

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -
Google search engine

Most Popular

Recent Comments